Disclosure Of Entity's Operating Segments [Text Block]

HEMOGENYX PHARMACEUTICALS PLC - Filing #5969073

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Disclosure of entity's operating segments [text block]
4
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Revenue
- GBP
- GBP
Tax expense (income)
- GBP
- GBP
Profit (loss) before tax
5,625,478 GBP
6,696,493 GBP
Profit (loss)
- GBP
- GBP
- GBP
5,619,181 GBP
6,297 GBP
5,625,478 GBP
- GBP
- GBP
- GBP
6,696,493 GBP
- GBP
5,815 GBP
6,690,678 GBP
- GBP
- GBP
- GBP
- GBP
- GBP
Assets
4,211,560 GBP
6,105,893 GBP
Liabilities
3,358,066 GBP
3,324,887 GBP
Cash flows from (used in) operating activities
4,140,059 GBP
6,105,570 GBP
Cash flows from (used in) investing activities
1,732 GBP
31,941 GBP
Cash flows from (used in) financing activities
3,077,453 GBP
4,449,311 GBP
Disclosure of products and services [text block]
Disclosure of products and services [abstract]
Disclosure of products and services [line items]
Disclosure of geographical areas [text block]
Disclosure of geographical areas [abstract]
Disclosure of geographical areas [line items]
Disclosure of major customers [text block]
Disclosure of major customers [abstract]
Disclosure of major customers [line items]

Talk to a Data Expert

Have a question? We'll get back to you promptly.